EMI (Encore Medical) Total Receivables: $1.27 Mil (As of Dec. 2025)


What is Encore Medical Total Receivables?

Encore Medical EMI Total Receivables is $1.27 Mil as of Dec. 2025.

Encore Medical's Total Receivables for the quarter that ended in Dec. 2025 was $1.27 Mil.

Encore Medical Total Receivables Related Terms

Encore Medical Total Receivables Historical Data

* Premium members only.

The historical data trend for Encore Medical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Total Receivables Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Total Receivables
0.38 0.35 1.27

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial 0.00 0.35 0.47 0.33 1.27

Encore Medical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $1.27 Mil mean?
Encore Medical (EMI) has a Total Receivables of $1.27 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Encore Medical and its competitors.
Is Encore Medical's Total Receivables too high?
Encore Medical's current Total Receivables is $1.27 Mil.
How does Encore Medical's Total Receivables compare to ?
Encore Medical's Total Receivables of $1.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Encore Medical and its competitors. Encore Medical's current Total Receivables is $1.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Total Receivables of $1.27 Mil. The current Total Receivables is $1.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Encore Medical (EMI), the current Total Receivables is $1.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).